Skip to main content
Premium Trial:

Request an Annual Quote

Santaris, Pfizer Expand LNA Drug Collaboration

Premium

Santaris Pharma said this week that its worldwide strategic alliance with Pfizer has been expanded, triggering a $14 million payment from the big pharma for access to Santaris' locked nucleic acid technology for the development of RNA-targeting drugs.

The deal was first struck in 2009 between Santaris and Wyeth (GSN 1/15/2009). Under the terms of the deal, Wyeth was to select up to 10 targets against which Santaris would create LNA-based drug candidates, although a Wyeth official told Gene Silencing News at the time that the company had no plans to pursue microRNA targets.

Pfizer inherited the partnership when it acquired Wyeth late in 2009.

Under the terms of the expanded arrangement, Santaris stands to receive up to $600 million in milestones, plus royalties, on products developed through the collaboration.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.